Kyowa Hakko Kirin California, Inc. (KKC) is a wholly-owned US subsidiary of Kyowa Hakko Kirin Co., Ltd. KKC serves as one of Kyowa Hakko Kirin's R&D centers in the United States, and facilitates the company's business and product development efforts in North America. We are focused on developing antibody based therapeutics in four major disease areas: oncology, renal diseases, immune disorders and allergy, by using proprietary technology such as the KM Mouse™, Potelligent® and Complegent®.
Since 1988, KKC has been a major corporate sponsor of the La Jolla Institute for Allergy and Immunology (LIAI), a not-for-profit research institute. In July 2006, together with LIAI, we moved to our new three-story state-of-the-art facility to further expand our research efforts on infectious diseases and disorders of the immune system. Our dedicated team is a focused and interactive group involved in pursuing innovative biomedical research and technologies targeted towards the development of novel therapeutics.
Click here to view press release
Kyowa Hakko Kirin announces the initiation of Phase 1-clinical trial of KRN23, a novel IV drug discovered by KHK for the treatment of X-linked Hypophosphatemia (XLH). XLH is a genetic metabolic condition which affects bone and teeth development.
As of January 1, 2009, Kirin Pharma USA has changed its name to Kyowa Hakko Kirin California, Inc.
(For more news releases, click here)
